Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

9.735 +1.515 (+18.43%)
Streaming Delayed Price Updated: 10:06 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024 ↗
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Seres Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 ↗
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss ↗
 
Via Benzinga
News headline image
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today ↗
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally. 
Via InvestorPlace
News headline image
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 ↗
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
News headline image
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today? ↗
Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections... 
Via Benzinga
News headline image
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November ↗
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.